A Phase I Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 29 Oct 2015
At a glance
- Drugs Imetelstat (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 26 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.